Baker Hughes Moves Closer to EC Approval for Chart Deal

Baker Hughes/Chart Industries: EC Clearance Anticipated After Parties Submitted Remedies on Friday, Sources Say

Baker Hughes (BKR) offered structural and behavioral remedies to the European Commission on Friday in a bid to secure approval for its $13.6 billion acquisition of Chart Industries (GTLS), concessions that are anticipated to pave the way for clearance, sources with direct knowledge of the matter said

Antibiotics Producer Warns ‘Buy European’ Rules Could Create Quasi-Monopoly

Dutch antibiotics producer Centrient is warning that a careless implementation of the “Buy European” criteria in the EU’s recently agreed Critical Medicines Act (CMA) could decrease competition...

Aug 25, 2026 Read Now >

Democratic Lawmakers—Including Warren and DeLauro—Back Federal Funding of State Antitrust Enforcement

Several Democratic lawmakers—including Senator Elizabeth Warren and Representative Rosa DeLauro, the likely Appropriations Committee chair if her party takes control of the House next year—say...

Aug 20, 2026 Read Now >

CFIUS Review Slowdown Extends Beyond DHS-Led Cases, Sources Say, Citing Staffing and Leadership Gaps; Heavier Reliance on Outside Contractors for Risk Assessments

The Committee on Foreign Investment in the United States (CFIUS) is experiencing a broader slowdown in merger reviews than the shutdown-driven backlog at the Department of Homeland Security (DHS)...

Aug 20, 2026 Read Now >

Baker Hughes/Chart Industries: EC Clearance Anticipated After Parties Submitted Remedies on Friday, Sources Say

RELATED ARTICLES | Antitrust Policy

Antibiotics Producer Warns ‘Buy European’ Rules Could Create Quasi-Monopoly

Democratic Lawmakers—Including Warren and DeLauro—Back Federal Funding of State Antitrust Enforcement

CFIUS Review Slowdown Extends Beyond DHS-Led Cases, Sources Say, Citing Staffing and Leadership Gaps; Heavier Reliance on Outside Contractors for Risk Assessments

FILTER BY

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.